The company reported net income in the first quarter of $81.4 million, or $0.44 per share, based on generally accepted accounting principles (GAAP).Bienaime said that BioMarin's team is preparing to launch the drug later this year and believes that it will be "the most innovative product yet for people with bleeding disorders."